Life Sciences Consulting M&A

Equiteq advises founder-led and PE-backed life sciences consulting firms, from strategy and clinical to regulatory, market access, technology and healthcare IT.

Talk to our life sciences team

Example Equiteq Transactions

Healthcare & life sciences-adjacent consulting.

See all transactions

August, 2026

Healthcare Tech

sold to

View Transaction Detail

August, 2025

Healthcare Consulting (Epic)

sold to

a portfolio company of

View Transaction Detail

December, 2024

Healthcare Tech

sold to

View Transaction Detail

January, 2024

Healthcare Consulting

invested in

View Transaction Detail

December, 2023

Healthcare Strategy

sold to

View Transaction Detail

October, 2023

Healthcare Automation

acquired

View Transaction Detail

April, 2021

Healthcare Transformation

equity financing led by

View Transaction Detail

January, 2018

Life Sciences

sold to

View Transaction Detail

December, 2017

Life Sciences

sold to

View Transaction Detail

May, 2016

Health Strategy Consulting

sold to

View Transaction Detail

1 / 3

M&A interest is shaped by the biggest global factors at play — ageing populations, accelerating innovation, and a historically conservative industry now adopting technology at scale. Buyers value firms that integrate AI and machine learning into drug discovery, personalised medicine and trial optimisation, and reward deep regulatory expertise alongside advanced data capability.

Paul Beaumont | Director
Contact Paul

Demand Intensity

One of the most active verticals in specialty consulting.

520
Deals in sector, 2018–2026 (Equiteq)
~75%
PE or PE-backed sponsors, 2018–2026
14.5x
Median EV/EBITDA, 2018–2026
200+
Equiteq transactions completed

Clients We Advise

Full value-chain coverage

Strategy & Commercial Due Diligence

Corporate and portfolio strategy, asset assessment and forecasting, BD support and commercial due diligence.

R&D & Clinical Services

CROs and functional service providers, clinical operations consulting, biometrics and data management.

Regulatory, Quality & Safety

Regulatory affairs, GxP quality, computer system validation, pharmacovigilance, and medtech and IVD regulatory.

Market Access, Pricing & HEOR

Pricing and reimbursement strategy, health economics, outcomes research and real-world evidence.

Commercialisation & Medical

Launch strategy, sales and marketing, medical affairs and communications, patient services and commercial analytics.

CMC, Supply Chain & Operations

Process development, manufacturing consulting, supply chain and operational excellence.

Life Sciences Technology & Data

Veeva and Salesforce implementation partners, eClinical, and data, analytics and AI services.

Healthcare IT

Provider and payer IT consulting, EHR implementation and optimisation, and healthcare data services.

What life sciences buyers are actually telling us.

59 buyer coverage calls referencing life sciences, across 51 distinct acquirers and sponsors, in the 12 months to October 2026.

Talk to our life sciences team

Live Signals

Deepest Demand
Regulatory and quality most wanted

Sponsors repeatedly describe regulatory, quality and validation consulting as a fragmented and attractive buy-and-build space. Several run dedicated regulatory platforms and are hunting bolt-ons across Europe and the US.

Hard Quality Bar
Real technology, not services as tech

Buyers look closely at technology depth, gross margin and recurring revenue to tell genuine data and AI-led platforms apart from consulting presented as a product. Proprietary data, IP and repeat revenue make a business more attractive.

Internationalisation
Transatlantic scale is a core thesis

Many active platforms want a combined UK/Europe and US footprint and are expanding across the Atlantic through bolt-ons, capex and hiring, including European groups seeking US acquisitions. Some sponsors still prioritise European-headquartered or UK-linked assets.

Adjacencies
Market access and commercialisation

Beyond regulatory, buyers prioritise market access, pricing, medical communications and commercialisation services, particularly capabilities that support assets from Phase 2-3 through launch and post-launch.

AI Reframe
AI is reframing which services survive

A recurring question from sponsors and strategic acquirers: as demand recovers, which consulting services remain critical and which are displaced by AI. Buyers favour specialist, harder-to-automate work, and some acquirers already use AI to automate parts of clinical data delivery.

Tech Services Buyers
IT services groups want pharma depth

Global IT and digital services groups list life sciences as a priority vertical and seek domain-led data, AI and platform capabilities, such as Veeva and Salesforce for life sciences, with access to large pharma clients. Most require profitable, growing assets.

Private equity drives roughly three-quarters of life sciences consulting M&A.

The private equity firms and strategic acquirers most active in life sciences consulting.
Accenture
Deloitte
EY
GlobalData
ICON
Indegene
Infosys
Inizio
IQVIA
McKesson
Parexel
ProPharma
Thermo Fisher
Trinity Life Sciences
Veeva
AEA Investors
Ampersand
Amulet Capital
Avesi Partners
Blackstone
Bridgepoint
Carlyle
EQT
Excellere
GHO Capital
Gilde Healthcare
Great Point Partners
Gyrus Capital
HIG Capital
IK Partners
Kester Capital
Keystone
Limerston
New Mountain Capital
Sheridan Capital
The Riverside Company

Why A Specialist

Four dimensions where a focused advisor changes the outcome.

Valuation methodologies

Life sciences consulting is not valued like generic professional services. An advisor needs to understand how scientific credibility, regulatory expertise, recurring-revenue quality and technology depth — not just headline EBITDA — drive the multiple.

The right buyer universe

The acquirers that pay premiums — listed CROs, large life sciences platforms and healthcare-focused sponsors — are a specialist set. Reaching them takes current, active coverage relationships, not a generic distribution list.

Sector-credible positioning

Buyers evaluate on capability breadth, regulated-market credibility and the durability of the science. Framing a business in their language is what separates a competitive process from a thin one.

A genuinely competitive process

Specialist coverage creates real competition among the right buyers at the same time — the difference between achieving a full price and selling to too few bidders at too low a price.

Relevant Resources

Categories: M&A trends

January 14, 2026

Life Sciences Consulting M&A Report 2026

Record deal volumes. Private equity dominance. Resilient valuations. Life sciences consulting M&A entered 2026 with sustained momentum, driven by private equity, ongoing healthcare transformation, and growing demand for tech-enabled, regulatory,...

Read more

Recent deals in life sciences consulting

Selected market transactions illustrating the themes above. Equiteq-advised deals are marked.

October 2026

Biomapas acquires Pinnaxis — pharmacovigilance technology and consulting, India

October 2026

TransPerfect acquires Synterex — AI-enabled medical and regulatory writing, US

September 2026

Clarenta Group, backed by EdgeCap Partners, acquires Leads To Development — regulatory, France

September 2026

TJP, backed by Renovus Capital, acquires Evolution Consulting & Research — market research, US

August 2026

Astrix, backed by Quad-C, acquires MAIN5 — regulatory and digital consulting, Germany

August 2026

PerkinElmer’s Project Farma agrees to acquire SimoTech — GMP automation and validation, Ireland

Frequently Asked Questions

Equiteq is a specialist global investment bank focused exclusively on M&A for tech-enabled and specialty consulting businesses, including life sciences consulting. We advise founder-led and PE-backed firms in strategy, clinical, regulatory and quality, market access, commercialisation, CMC and operations, technology and healthcare IT, on sell-side, buy-side and capital-raise mandates.

Our coverage spans eight segments: strategy consulting and commercial due diligence; R&D and clinical services, including CROs and FSPs; regulatory, quality and safety, including validation and pharmacovigilance; market access, pricing and HEOR; commercialisation and medical affairs; CMC, supply chain and operations; life sciences technology and data services; and healthcare IT.

Two groups. Strategic acquirers and platforms: listed CROs such as IQVIA and ICON, advisory platforms such as Parexel, Inizio and ProPharma, data players such as Thermo Fisher (now owner of Clario) and diversified consultancies. Second, private equity firms with healthcare teams, including GHO Capital, Bridgepoint, New Mountain, Gilde Healthcare, HIG and Kester. PE drives roughly 75% of deals.

Valuations are driven by scale, growth and margin. Equiteq's 2026 analysis put recent life sciences and healthcare deals at a median of roughly 3.1x LTM revenue and 14.5x LTM EBITDA in private markets, above the aggregate public-market level. Disclosed multiples typically relate to larger businesses, so boutique consultancies should calibrate expectations accordingly.

The global life sciences consulting market is growing at over 9% a year toward roughly $52bn by 2030, driven by demand for advanced therapeutics and digital transformation in healthcare. A scarcity of high-quality mid-size consultancies, heavy private equity involvement and rising regulatory complexity are all fuelling competition for assets.

In Equiteq's buyer coverage conversations, the most-wanted capability is regulatory, quality and validation consulting, a fragmented buy-and-build space. Market access and commercialisation is a consistent second priority; CRO and clinical data services also feature. Buyers test technology depth, margin and recurring revenue to separate data-led platforms from services sold as technology.

Yes. A combined UK/Europe and US footprint is a common platform thesis in the sector, and many active acquirers are adding capability across the Atlantic through bolt-ons and hiring. Equiteq runs cross-border processes across North America, Europe and Asia Pacific, with in-country execution support, connecting clients to the regional and global acquirers most likely to value their capability.

Equiteq has completed 200+ transactions in the consulting and technology services segments, with around 85% sell-side, a deal size range of £20–200m, and approximately 40 active mandates at any time.

Buyers pay for scientific credibility, depth in regulated markets, revenue quality and genuine technology or data assets rather than services presented as a product. Client concentration, key-person dependency and undifferentiated delivery all compress value. For founders not yet ready to go to market, Equiteq runs a strategic review that assesses the business through a buyer's lens.